1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. Roche Acquires CAPP Medical

M&A Deal Summary

Roche Acquires CAPP Medical

On April 13, 2015, Roche acquired medical products company CAPP Medical

Acquisition Highlights
  • This is Roche’s 4th transaction in the Medical Products sector.
  • This is Roche’s 13th transaction in the United States.
  • This is Roche’s 7th transaction in California.

M&A Deal Summary
Date 2015-04-13
Target CAPP Medical
Sector Medical Products
Buyer(s) Roche
Deal Type Add-on Acquisition

Target

CAPP Medical

Palo Alto, California, United States
CAPP Medical is a developer of disruptive liquid non-invasive cancer detection technology using next generation DNA sequencing.

Search 205,121 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Roche

Basel, Switzerland
Category Company
Founded 1896
Sector Life Science
Employees100,920
Revenue 60.4B CHF (2023)
DESCRIPTION
Roche's corporate headquarters in Basel, Switzerland.
Roche's corporate headquarters in Basel, Switzerland.

Roche is a research-focused healthcare company focused on pharmaceuticals and diagnostics. Roche offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche was founded in 1896 and is based in Basel, Switzerland.

DEAL STATS #
Overall 24 of 42
Sector (Medical Products) 4 of 5
Type (Add-on Acquisition) 22 of 35
State (California) 7 of 14
Country (United States) 13 of 28
Year (2015) 2 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-01-16 Trophos SA

Marseille, France

Trophos is a late stage clinical stage company with a pipeline of original molecules in development for neurological and cardiac diseases. These diseases include spinal muscular atrophy (SMA), Multiple Sclerosis (MS) disability progression and Cardiac Ischemia-Reperfusion Injury (IRI). Trophos additionally has collaborative research projects in other neurological conditions.

Buy €470M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-08-13 GeneWeave BioSciences

Los Gatos, California, United States

GeneWeave BioSciences, Inc. is a privately-held in vitro diagnostics company that is advancing clinical microbiology with diagnostic solutions to aid healthcare providers in the fight against drug-resistant bacteria by enabling impactful surveillance programs, early therapy guidance and successful antibiotic stewardship.

Buy $425M
Mergr

Product

Company

Legal